Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
7.05
+0.46 (6.98%)
At close: Mar 9, 2026, 4:00 PM EDT
6.88
-0.17 (-2.41%)
After-hours: Mar 9, 2026, 7:14 PM EDT
Unicycive Therapeutics Employees
As of December 31, 2024, Unicycive Therapeutics had 23 total employees, including 22 full-time and 1 part-time employees. The number of employees increased by 9 or 64.29% compared to the previous year.
Employees
23
Change (1Y)
9
Growth (1Y)
64.29%
Revenue / Employee
n/a
Profits / Employee
-$1,452,696
Market Cap
151.51M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23 | 9 | 64.29% |
| Dec 31, 2023 | 14 | 2 | 16.67% |
| Dec 31, 2022 | 12 | 3 | 33.33% |
| Dec 31, 2021 | 9 | 8 | 800.00% |
| Dec 31, 2020 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 341 |
| Sangamo Therapeutics | 183 |
| Innate Pharma | 174 |
| Zentalis Pharmaceuticals | 166 |
| Fate Therapeutics | 161 |
| Adagene | 138 |
| Artiva Biotherapeutics | 106 |
| Connect Biopharma Holdings | 62 |
UNCY News
- 20 days ago - Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf - Newsfile Corp
- 4 weeks ago - Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit - GlobeNewsWire
- 5 weeks ago - Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile - Seeking Alpha
- 5 weeks ago - UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - GlobeNewsWire
- 5 weeks ago - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - GlobeNewsWire
- 2 months ago - Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) - GlobeNewsWire
- 3 months ago - Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf - Newsfile Corp
- 3 months ago - Unicycive Therapeutics to Participate in Upcoming Investor Events in December - GlobeNewsWire